Study Comparing Vaginal Repair With and Without Leuprorelin in Women with Cesarean Section Scar Defect and Adenomyosis

What this Trial Is About

This research aims to evaluate the effects of vaginal repair surgery combined with Leuprorelin compared to vaginal repair alone in women diagnosed with Cesarean Section Scar Defect CSD complicated by adenomyosis. The study focuses on whether postponing the menstrual period after surgery can improve the healing and prognosis of the scar tissue. Women enrolled in the study will have abnormal uterine bleeding and prolonged menstrual flow related to their condition. Participants will undergo vaginal excision and suturing of the CSD. One group will receive subcutaneous injections of Leuprorelin three times over four weeks around the time of surgery to temporarily delay menstruation, which may reduce local inflammation and improve uterine conditions. The other group will receive vaginal repair without Leuprorelin. Both groups will be followed up to assess outcomes. During the study, participants will be examined at 6 months after surgery, with primary measures taken 12 weeks post-operation including the thickness of the remaining muscular layer at the scar site and the duration of menstruation. Researchers will monitor healing and changes in uterine tissue to assess the impact of the delayed period treatment. The study is randomized and open-label, with participation lasting from surgery to follow-up assessments.

Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect